Know Cancer

or
forgot password

A Phase I Trial of ABI-009 (Nab-rapamycin) Administered Weekly in Patients With Advanced Non-hematologic Malignancies


Phase 1
18 Years
N/A
Not Enrolling
Both
Solid Tumors

Thank you

Trial Information

A Phase I Trial of ABI-009 (Nab-rapamycin) Administered Weekly in Patients With Advanced Non-hematologic Malignancies


No extended description necessary


Inclusion Criteria:



Each subject must meet the following criteria to be enrolled in this study.

1. Male and female patients with histologically or cytologically confirmed diagnosis of
cancer which is not amenable to curative therapy.

2. Patients with advanced non-hematologic malignancies for whom no standard therapy
exists.

3. Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, pleural
effusion, ascites, or lesions which do not fulfill RECIST criteria for metastatic
disease)

4. Off all therapy (inclusive of investigational therapies) for at least 4 weeks prior
to study drug administration OR off all daily or weekly therapy (inclusive of
investigational therapies) for at least 2 weeks prior to study drug administration
and without any side effects associated with these therapies.

5. Female patients of child-bearing potential must have a negative serum pregnancy test
within 7 days prior to first study drug administration.

6. Female patients who are postmenopausal must have 12 months of amenorrhea, surgically
sterile, or must agree to the use of a physical method of non-hormonal contraception.

7. Male patients must be surgically sterile or agree to the use of a barrier method of
contraception.

8. Life expectancy of > 3 months.

9. ECOG Performance Status of 0-1.

10. Patients must be able to provide informed consent indicating knowledge of his/her
disease process, the investigational nature of the therapy, alternatives, benefits,
and risks including potential side effects.

11. Age ≥ 18 years of age.

12. No major surgery within 4 weeks before treatment with ABI-009. (A biopsy is not
considered major surgery).

13. No chemotherapy, hormonal therapy, immunotherapy or radiotherapy within 4 weeks
before treatment with ABI-009 (6 weeks for previous treatment with nitrosoureas,
mitomycin, or extensive radiotherapy) and no immunosuppressive agents within 3 weeks
before study entry (except corticosteroids used as antiemetics).

14. No immunosuppressive agents within 3 weeks before study entry (except corticosteroids
used as antiemetics).

15. Required Initial Laboratory Data:

- Hemoglobin > 9.0 g/dL

- WBC ≥ 3,000/µl

- ANC ≥ 1,500/µl

- Platelet count ≥ 100,000/µl

- Total Bilirubin ≤ ULN

- SGOT (AST) SGPT (ALT) ≤ 1.5 x ULN ≤ 1.5 x ULN

- Serum Cholesterol < 350 mg/dL

- Serum Triglyceride < 300 mg/dL

16. Adequate renal function with serum creatinine < 1.5 mg/dL and/or creatinine clearance
(cockroft formula) ≥ 60 mL/min.

17. No active alcohol abuse, drug addiction, or psychotic disorders.

18. No known concomitant genetic or acquired immunosuppressive diseases (such as AIDS).

19. If obese, a patient must be treated with doses calculated using his/her actual BSA
(The physician must be comfortable treating at the full BSA dose regardless of BSA).

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study.

1. Pregnant or nursing women.

2. History of allergic reactions attributed to compounds of similar chemical or biologic
composition including macrolide (e.g. azithromycin, clarithromycin, dirithromycin,
and erythromycin) and ketolide antibiotics.

3. Patients have not recovered from adverse affects of radiation therapy or
investigational agent within previous 28 days.

4. Uncontrolled intercurrent illness that in the opinion of the investigator would limit
compliance and tolerance to study requirements

5. Patients with known brain metastases or leptomeningeal tumor involvement.

6. Receiving any of the following: concomitant antitumor therapy or inhibitors of
CYP3A4.

7. Patients with history of interstitial lung disease and/or pneumonitis.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 administered weekly and pharmacokinetic parameters for ABI-009.

Outcome Time Frame:

End of Study (EOS) and Follow Up

Safety Issue:

Yes

Principal Investigator

Ana M. Gonzalez, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

CA401

NCT ID:

NCT00635284

Start Date:

December 2007

Completion Date:

June 2011

Related Keywords:

  • Solid Tumors

Name

Location

University of Texas M.D. Anderson Cancer CenterHouston, Texas  77030
Sarcoma Oncology CenterSanta Monica, California  90403